Recent advances in the understanding and management of delayed puberty

Archives of Disease in Childhood

Volumn 101, Issue 5, 2016, Pages 481-488

  Wei, Christina ^a,b   Crowne, Elizabeth Clare ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCRINE DISRUPTOR; GONADORELIN; GONADORELIN AGONIST; GONADOTROPIN; INHIBIN B; KISSPEPTIN 10; MUELLERIAN INHIBITING FACTOR; SEX HORMONE; TESTOSTERONE;

ADOLESCENT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DELAYED PUBERTY; DIAGNOSTIC ACCURACY; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE MUTATION; GENETICS; HORMONAL THERAPY; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT HEALTH; CHILD; DIFFERENTIAL DIAGNOSIS; HORMONE SUBSTITUTION; MALE; PATHOPHYSIOLOGY; PROCEDURES; PUBERTY, DELAYED; SEXUAL MATURATION;

ADOLESCENT HEALTH; CHILD; DIAGNOSIS, DIFFERENTIAL; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PUBERTY, DELAYED; SEXUAL MATURATION;

EID: 84941695921     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-307963     Document Type: Article

References (58)

1. Palmert MR, Boepple PA. Commentary: variation in the timing of puberty: clinical spectrum and genetic investigation. J Clin Endocrinol Metab 2001;86:2364-8.
2. Day FR, Elks CE, Murray A, et al. Puberty timing associated with diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank study. Sci Rep 2015;5:11208.
3. Childhood Growth Foundation. Boys four-in-one growth charts (Birth-20 years). UK Cross-sectional reference data:1996/1 (updated in 2002 for use with 5% and 95% thrive lines). Harlow Printing Ltd.
4. Childhood Growth Foundation. Girls four-in-one growth charts (Birth-20 years). UK Cross-sectional reference data:1996/1 (updated in 2002 for use with 5% and 95% thrive lines). Harlow Printing Ltd.
5. Sedlmeyer IL, Palmert MR, Hospital C. Delayed puberty: Analysis of a large case series from an academic center. J Clin Endocrinol Metab 2002;87:1613-20.
6. Kuiri-Hänninen T, Sankilampi U, Dunkel L. Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. Horm Res Paediatr 2014;82:73-80.
7. Conte FA, Grumbach MM, Kaplan SL. A diphasic pattern of gonadotropin secretion in patients with the syndrome of gonadal dysgenesis. J Clin Endocrinol Metab 1975;40:670-4.
8. Grinspon RP, Ropelato MG, Bedecarrás P, et al. Gonadotrophin secretion pattern in anorchid boys from birth to pubertal age: Pathophysiological aspects and diagnostic usefulness. Clin Endocrinol (Oxf) 2012;76:698-705.
9. De Roux N, Genin E, Carel J-C, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100:10972-6.
10. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614-27.
11. Kaur KK, Allahbadia G, Singh M. Kisspeptins in human reproduction-future therapeutic potential. J Assist Reprod Genet 2012;29:999-1011.
12. Uenoyama Y, Tsukamura H, Maeda KI. KNDy neuron as a gatekeeper of puberty onset. J Obstet Gynaecol Res 2014;40:1518-26.
13. Wehkalampi K, Widén E, Laine T, et al. Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. J Clin Endocrinol Metab 2008;93:723-8.
14. He C, Murabito JM. Genome-wide association studies of age at menarche and age at natural menopause. Mol Cell Endocrinol 2014;382:767-79.
15. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 2003;24:668-93.
16. Sedlmeyer IL, Hirschhorn JN, Palmert MR. Pedigree analysis of constitutional delay of growth and maturation: Determination of familial aggregation and inheritance patterns. J Clin Endocrinol Metab 2002;87:5581-6.
17. Bonomi M, Libri DV, Guizzardi F, et al. New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian J Androl 2012;14:49-56.
18. Zhu J, Choa RE-Y, Guo MH, et al. A shared genetic basis for self-limited delayed puberty and idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2015;100:E646-54.
19. Vaaralahti K, Wehkalampi K, Tommiska J, et al. The role of gene defects underlying isolated hypogonadotropic hypogonadism in patients with constitutional delay of growth and puberty. Fertil Steril 2011;95:2756-8.
20. Elks CE, Perry JRB, Sulem P, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet 2010;42:1077-85.
21. Perry JRB, Day F, Elks CE, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature 2014;514:92-7.
22. Ong KK, Elks CE, Li S, et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat Genet 2009;41:729-33.
23. Cousminer DL, Stergiakouli E, Berry DJ, et al. Genome-wide association study of sexual maturation in males and females highlights a role for body mass and menarche loci in male puberty. Hum Mol Genet 2014;23:4452-64.
24. Rzeczkowska PA, Hou H, Wilson MD, et al. Epigenetics: a new player in the regulation of mammalian puberty. Neuroendocrinology 2014;99:139-55.
25. Abreu AP, Macedo DB, Brito VN, et al. A new pathway in the control of the initiation of puberty: the MKRN3 gene. J Mol Endocrinol 2015;54:R131-9.
26. Han JC, Lawlor DA, Kimm SYS. Childhood obesity. Lancet 2010;375:1737-48.
27. Lee PA, Guo SS, Kulin HE. Age of puberty: data from the United States of America. APMIS 2001;109:81-8.
28. Wagner IV, Sabin MA, Pfäffle RW, et al. Effects of obesity on human sexual development. Nat Rev Endocrinol 2012;8:246-54.
29. Nathan BM, Sedlmeyer IL, Palmert MR. Impact of body mass index on growth in boys with delayed puberty. J Pediatr Endocrinol Metab 2006;19:971-7.
30. Roelants M, Hauspie R, Hoppenbrouwers K. References for growth and pubertal development from birth to 21 years in Flanders, Belgium. Ann Hum Biol 2009;36:680-94.
31. Sørensen K, Aksglaede L, Petersen JH, et al. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab 2010;95:263-70.
32. Aksglaede L, Sørensen K, Petersen JH, et al. Recent decline in age at breast development: the Copenhagen Puberty Study. Pediatrics 2009;123:e932-9.
33. Parent A, Franssen D, Fudvoye J, et al. Developmental variations in environmental influences including endocrine disruptors on pubertal timing and neuroendocrine control: Revision of human observations and mechanistic insight from rodents. Front Neuroendocrinol 2015;38:12-36.
34. Jasik CB, Lustig RH. Adolescent obesity and puberty: the 'perfect storm'. Ann N Y Acad Sci 2008;1135:265-79.
35. Burt Solorzano CM, McCartney CR. Obesity and the pubertal transition in girls and boys. Reproduction 2010;140:399-410.
36. Van Buuren S, Ooms JCL. Stage line diagram: an age-conditional reference diagram for tracking development. Stat Med 2009;28:1569-79.
37. Harrington J, Palmert MR. Distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism: Critical appraisal of available diagnostic tests. J Clin Endocrinol Metab 2012;97:3056-67.
38. Sequera AM, Fideleff HL, Boquete HR, et al. Basal ultrasensitive LH assay: a useful tool in the early diagnosis of male pubertal delay? J Pediatr Endocrinol Metab 2002;15:589-96.
39. Segal TY, Mehta A, Anazodo A, et al. Role of Gonadotropin-Releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J Clin Endocrinol Metab 2009;94:780-5.
40. Binder G, Schweizer R, Blumenstock G, et al. Inhibin B plus LH vs GnRH agonist test for distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism in boys. Clin Endocrinol (Oxf) 2015;82:100-5.
41. Brougham MFH, Crofton PM, Johnson EJ, et al. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012;97:2059-67.
42. Raivio T, Falardeau J, Dwyer A, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357:863-73.
43. Mayo A, Macintyre H, Wallace AM, et al. Transdermal testosterone application: pharmacokinetics and effects on pubertal status, short-term growth, and bone turnover. J Clin Endocrinol Metab 2004;89:681-7.
44. Khairi R, Shaw N, Crowne E. British Society of Paediatric Endocrinology Diabetes Endorsed Guidelines: Testosterone Replacement Therapy. 2013. http://www.bsped.org.uk/clinical/docs/TestosteroneReplacementGuideline.pdf
45. Phelan N, Conway SH, Llahana S, et al. Quantification of the adverse effect of ethinylestradiol containing oral contraceptive pills when used in conjunction with growth hormone replacement in routine practice. Clin Endocrinol (Oxf) 2012;76:729-33.
46. Nabhan ZM, DiMeglio LA, Qi R, et al. Conjugated oral versus transdermal estrogen replacement in girls with turner syndrome: a pilot comparative study. J Clin Endocrinol Metab 2009;94:2009-14.
47. Shah S, Forghani N, Durham E, et al. A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism. Int J Pediatr Endocrinol 2014;2014:12.
48. Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ 2011;342:d1980.
49. Ankarberg-Lindgren C, Kriström B, Norjavaara E. Physiological estrogen replacement therapy for puberty induction in girls: a clinical observational study. Horm Res Paediatr 2014;81:239-44.
50. Quigley C, Wan X, Garg S, et al. Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial. JCEM 2014;99:E1754-64.
51. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med 2011;364:1230-42.
52. Delemarre EM, Felius B, Delemarre-Van De Waal HA. Inducing puberty. Eur J Endocrinol 2008;159(Suppl 1):S9-15.
53. Eiholzer U, Grieser J, Schlumpf M, et al. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome. Horm Res 2007;68:178-84.
54. Dwyer AA, Sykiotis GP, Hayes FJ, et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013;98:E1790-5.
55. Raivio T, Wikström AM, Dunkel L. Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur J Endocrinol 2007;156:105-11.
56. Pitteloud N, Hayes FJ, Dwyer A, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:4128-36.
57. George JT, Veldhuis JD, Tena-Sempere M, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clin Endocrinol (Oxf) 2013;79:100-4.
58. Dunkel L, Quinton R. Transition in endocrinology: induction of puberty. Eur J Endocrinol 2014;170:R229-39.